DK1789079T3 - Insulinregulrede aminopeptidase (IRAP)-inhibitorer og anvendelser deraf - Google Patents

Insulinregulrede aminopeptidase (IRAP)-inhibitorer og anvendelser deraf

Info

Publication number
DK1789079T3
DK1789079T3 DK05778990.1T DK05778990T DK1789079T3 DK 1789079 T3 DK1789079 T3 DK 1789079T3 DK 05778990 T DK05778990 T DK 05778990T DK 1789079 T3 DK1789079 T3 DK 1789079T3
Authority
DK
Denmark
Prior art keywords
irap
insulin
inhibitors
regulated aminopeptidase
aminopeptidase
Prior art date
Application number
DK05778990.1T
Other languages
Danish (da)
English (en)
Inventor
Siew Yeen Chai
Michael William Parker
Anthony Lloyd Albiston
Craig J Morton
Hooi Ling Ng
Siying Ye
Frederick A O Mendelsohn
Original Assignee
Florey Howard Inst
St Vincents Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905182A external-priority patent/AU2004905182A0/en
Application filed by Florey Howard Inst, St Vincents Inst Med Res filed Critical Florey Howard Inst
Application granted granted Critical
Publication of DK1789079T3 publication Critical patent/DK1789079T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
DK05778990.1T 2004-09-09 2005-09-09 Insulinregulrede aminopeptidase (IRAP)-inhibitorer og anvendelser deraf DK1789079T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004905182A AU2004905182A0 (en) 2004-09-09 Enzyme inhibitors and uses thereof
PCT/AU2005/001380 WO2006026832A1 (en) 2004-09-09 2005-09-09 Enzyme inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
DK1789079T3 true DK1789079T3 (da) 2013-03-11

Family

ID=36036029

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05778990.1T DK1789079T3 (da) 2004-09-09 2005-09-09 Insulinregulrede aminopeptidase (IRAP)-inhibitorer og anvendelser deraf

Country Status (13)

Country Link
US (1) US20080194636A1 (cg-RX-API-DMAC7.html)
EP (1) EP1789079B1 (cg-RX-API-DMAC7.html)
JP (1) JP5031567B2 (cg-RX-API-DMAC7.html)
KR (1) KR20070100878A (cg-RX-API-DMAC7.html)
CN (1) CN101039690A (cg-RX-API-DMAC7.html)
CA (1) CA2579768A1 (cg-RX-API-DMAC7.html)
DK (1) DK1789079T3 (cg-RX-API-DMAC7.html)
ES (1) ES2403340T3 (cg-RX-API-DMAC7.html)
IL (1) IL181819A (cg-RX-API-DMAC7.html)
NZ (1) NZ553688A (cg-RX-API-DMAC7.html)
SG (1) SG155901A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006026832A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200702041B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263775B2 (en) 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
CN101284820B (zh) * 2008-04-25 2011-05-04 南昌大学 一种氨肽酶抑制剂及合成方法
CN103848805A (zh) * 2012-12-06 2014-06-11 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103896900A (zh) * 2012-12-25 2014-07-02 韩冰 一类具有神经保护作用的化合物及其制备方法和用途
PL3150581T3 (pl) 2014-05-28 2020-07-13 Astellas Pharma Inc. Pochodne pirydyny
AR102849A1 (es) 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
WO2017015720A1 (en) 2015-07-30 2017-02-02 Monash University Fibrotic treatment
WO2023099589A1 (en) 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5281619A (en) 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
EP1004584A3 (en) 1992-11-18 2000-07-05 Eli Lilly And Company Limited Pyranoquinoline derivatives as inhibitors of cell proliferation
US6680332B1 (en) * 1999-06-04 2004-01-20 Euro-Celtique S.A. Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA
EP1392683B1 (en) * 2001-05-16 2009-12-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and their use as anticancer agents
US20050020519A1 (en) * 2001-08-02 2005-01-27 Albiston Anthony L. Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at4) receptor activity
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
PL372488A1 (en) * 2002-02-13 2005-07-25 F.Hoffmann-La Roche Ag Novel pyridine- and quinoline-derivatives
US8263775B2 (en) * 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof

Also Published As

Publication number Publication date
IL181819A0 (en) 2007-07-04
EP1789079B1 (en) 2012-11-07
JP5031567B2 (ja) 2012-09-19
US20080194636A1 (en) 2008-08-14
EP1789079A4 (en) 2010-09-01
SG155901A1 (en) 2009-10-29
IL181819A (en) 2013-07-31
JP2008512395A (ja) 2008-04-24
EP1789079A1 (en) 2007-05-30
NZ553688A (en) 2011-05-27
CN101039690A (zh) 2007-09-19
ZA200702041B (en) 2008-09-25
CA2579768A1 (en) 2006-03-16
WO2006026832A1 (en) 2006-03-16
ES2403340T3 (es) 2013-05-17
KR20070100878A (ko) 2007-10-12

Similar Documents

Publication Publication Date Title
NO2017017I1 (no) umeklinidium og vilanterol
FI20055430A0 (fi) Piiri Doherty-vahvistimien rinnankäyttöä varten
PT1586571E (pt) Inibidores da dipeptidil-peptidase
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
EP1812049A4 (en) KALLIKREIN INHIBITORS AND USES THEREOF
EP1789381A4 (en) INHIBITORS OF HISTONE DEACETYLASE
CY2014012I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
IL192134A0 (en) Soft protease inhibitors and pro-soft forms thereof
CY2013042I1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
EP1742627A4 (en) PDE4B HEMMER AND ITS USE
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK1753406T4 (da) Overtrukket tabletformulering og fremgangsmåde
DK2305250T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
ATE521604T1 (de) N-substituierte benzimidazolyl-c-kit-inhibitoren und kombinatorische benzimidazolbibliothek
DK1771421T3 (da) N-hydroxyamidderivater og anvendelse deraf
DE602004018837D1 (de) Ptidase-iv-inhibitoren
EP1817276A4 (en) CATHEPSINCYSTEINPROTEASEHEMMER
DK1685150T3 (da) Hidtil ukendte 17beta-hydroxysteroiddehydrogenase type I-inhibitorer
DK1723135T3 (da) Kendte hydroxy-6-heteroarylphenanthridiner og deres anvendelse som pde4-inhibitorer
ATE545642T1 (de) Mmp-inhibitoren
EP2262797A4 (en) INHIBITORS OF INSULIN REGULATED AMINO PEPTIDASE (IRAP) AND APPLICATIONS THEREOF
DK1885716T3 (da) Thiazolderivater og anvendelse deraf